Spark Therapeutics Inc. said its expects to be advancing 10 clinical-stage gene therapy programs by 2018, all fully funded with existing financial resources.
The plan, according to Spark CEO and co-founder Jeffrey D. Marrazzo, includes having its first commercial product in the market in 2017 and having two other new gene therapy candidates in late-stage testing by that time.
Marrazzo made his comment this week during J.P. Morgan annual health care conference in San Francisco.
